Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price target of $100, implying a potential upside of nearly 172% from the current price. This optimism is driven by the company’s lead candidate, Claseprubart, which is what they refer to as a “best-in-class complement inhibitor.” The research firm believes that Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is in a good p ...